A B S T R A C T Studies were performed to examine synthesis, tissue localization, and metabolism of mevalonic acid in normal rats. Circulating mevalonate was found to have a rapid turnover phase of 5 min and a slower phase of 40-50 min. Under in vitro conditions the synthesis of mevalonate is carried out most actively by the liver and only to a minor extent by the other tissues studied. The most unexpected finding of this study was that both in vivo and in vitro the kidneys rather than the liver are the primary site of the metabolism of circulating mevalonate. Whereas mevalonate in the liver is rapidly transformed to cholesterol, the major products of mevalonate metabolism in the renal tissues during the same time period are squalene and lanosterol. Exogenous in contrast to circulating mevalonate is metabolized primarily in the intestine.
INTRODUCTION
There is now abundant evidence that mevalonic acid is an essential intermediate in the synthesis of all animal and plant sterols (1, 2) . In addition, previous studies from this laboratory have established that the reaction responsible for the synthesis of mevalonate represents the primary site of feedback control of cholesterol biosynthesis (3, 4) , a finding that has been confirmed by a number of subsequent reports (5) (6) (7) . Finally vitro (8) (9) (10) (11) and in vivo studies (12) to be regularly lost following malignant change in liver. This lesion, moreover, remains the single known example of thie constant loss of a normal feedback system in cancerous tissue (13) .
The finding that mevalonic acid plays so key a regulatory function in sterol synthesis serves to emphasize the need for a better knowledge of the metabolic fate of this compound than is currently available. While numerous studies have examined this problem in isolated in vitro systems (1, 2, 14-16), relatively few studies have been directed at the more physiologic question of the metabolic fate of mevalonic acid in the intact animal.
Gould and Popjak (17) first observed in 1957 that injected DL-[14C]mevalonic acid tended to concentrate in the liver of the rat. Subsequently, Goodman, Avigan, and Steinberg (18) confirmed and expanded this observation by demonstrating that in the rat intravenously administered DL-[2-14C]mevalonate was rapidly taken up by the liver and there converted into the nonsaponifiable intermediates of cholesterol synthesis. Finally, Garattini, Paoletti, and Paoletti (19) also noted that 2 h after the administration of [14C] mevalonate to rats the label was found primarily in the liver.
It is noteworthy that, while each of these earlier studies indicated that intravenously administered mevalonate is metabolized by the liver, only the study of Garattini et al. (19) attempted to assess the relative importance of the other tissues of the body in the overall metabolism of mevalonate.
It was the purpose of the present study to determine whether organs other than the liver play a role in the metabolism of endogenous mevalonate. The unexpected result of these studies is that the major portion of circulating mevalonate is metabolized not by the liver but by kidneys. METHODS Animals. Unless otherwise indicated the rats employed in this study were The free L-[1-'4Cmevalonate was then rechromatographed in the same solvent system, and the free mevalonate at the front was recovered by elution of the silica gel with Nanograde methanol. Analysis of the product by gas-liquid chromatography demonstrated that at least 90% of the recovered 4C was present in mevalonic acid.
Analytical methods. The various tissues to be studied were cut into small pieces and extracted for 2 h by refluxing repeatedly with chloroform-methanol (1: 1 by volume). A portion of this extract, one-fourth to one-third, was then transferred into a 50 ml screw tube and evaporated to dryness under a stream of nitrogen. 2 ml of 1 N potassium hydroxide in 35% ethanol were added per gram of tissue represented in the evaporated extract. The tubes were then flushed with nitrogen, closed with a screw cap and placed in a waterbath (70°C) for 1 h. The lipids were next separated into the nonsaponifiable fraction, the allyl pyrophosphates and the prenoic acids by the method described by Goodman and Popjak (16) The turnover times of DL-and L-mevalonate were determined as follows: Cannulae of P-10 polyethylene tubing were inserted into the femoral arteries and the tail veins of lightly anesthetized rats. The rats were then placed in restraining cages and allowed to recover for at least 1 h. The labeled mevalonate was then injected through the venous cannulae, and at regular intervals 50 ,ul of blood was collected from the femoral artery and added to 1.0 ml of 0.9%o saline. A 0.6 ml portion of the diluted blood was then directly assayed for 14C using Beckman Bio-Solve 38 as the scintillation solution.
Mevalonate synthesis by tissue slices was determined exactly as described in a previous publication (3) . The further details of the individual experiments are described under Results.
RESULTS

Kinetic studies of mevalonate in vivo
Turnover time of mevalonate in normal rats. The initial experiments of this study were designed to determine the rate at which circulating mevalonate is metabolized in the normal rat. The turnover time of a relatively small dose of mevalonate was estimated by injecting 7 (20) .
200 g Sprague-Dawley rat. The resulting die-away curves were analyzed according to the two-pool model described by Gurpide, Mann, and Sandberg (20) . After an initial rapid decrease in blood radioactivity with a corrected turnover time that can be approximated at 7 min ( Fig. 1 ), a somewhat slower turnover rate with a half-time of 28 min and a turnover time of 40 min was observed.
Both because of the possibility of the incorporation of ['H]mevalonate into circulating labeled compounds other than mevalonate and because of the complicating problem of the nonphysiologic D-mevalonate influencing the turnover kinetics of administered DL-mevalonate, these turnover studies were repeated using the physiologically active L-isomer of mevalonate, prepared as described under Methods. In addition, in this experiment the mevalonate was labeled in the carboxyl carbon. The metabolism of mevalonate to isopentenyl pyrophosphate results in the loss of its first carbon as 'CO2, which in turn is diluted by the large body pool of '2CO2 and expired; as a result it would be highly unlikely that significant amounts of "C present in the blood of the rat injected with L-[1-"C]mevalonate would be present in compounds other than mevalonate itself. As shown in 
Metabolism of endogenous mevalonate
Tissue distribution of circulating mevalonate. Studies were next carried out to determine where within the body the metabolism of this circulating endogenous pool of mevalonate takes place. The initial experiments were designed to determine the overall tissue distribution and relative affinities of various organs for endogenous mevalonic acid. Accordingly, DL-[2-14C]mevalonate (150 t'g or 75 lyg of L-mevalonate) were injected intravenously into rats, the animals were killed 2 h later, and the total 14C recovered in the various tissues following chloroform and methanol extraction was determined. The results shown in Fig. 3 the kidneys, rather than the liver, represent the major site of uptake of the "C, with four times as much of the label being present in the kidney (16%) as was found in the liver (3.9%). The entire gastrointestinal tract and its contents accumulated a total of only 2.4% of the recovered radioactivity with lesser amounts of radioactivity being found in the other tissues examined. It was assumed that the remainder of the mevalonate and its metabolites were either distributed throughout the carcass, which was not examined, or else excreted in the urine. The ability of the kidneys to accumulate mevalonate and its metabolites is even more strikingly demonstrated when the distribution of the label is calculated on the basis of the weight of the tissues studied. As is shown in Fig. 4 Since only the L form of mevalonate is metabolized in the body, actually 30% of the "metabolizable" mevalonate is present in the kidneys at this time interval. By contrast, the liver, 30 min after injection of mevalonate, contained only 3% of the administered 14C as metabolic products of mevalonate, while the intestine accumulated only 0.5% of the label during this 30 min period. Moreover, this predominance of the kidneys in mevalonate metabolism persists throughout the 1st and 2nd h after administration of the [1'C]mevalonate, and in fact the relative concentration of the label in the kidneys is more marked at the 4th h of the study, at which time over 20 times the amount of 14C is found in the kidneys than is present in the liver.
The data in Fig. 5 As indicated in Fig. 6 , when the labeled mevalonate was administered by the intraperitoneal route, an identical tissue distribution of 14C was observed even after 48 h. Moreover, the pattern of mevalonate metabolism, with the predominance of label in the nonsaponifiable fraction of the kidneys, which was observed following the intravenous administration of mevalonate, was confirmed when the labeled mevalonate was given by the intraperitoneal route.
Taken together these studies therefore provide strong evidence not only that the kidney serves as the major tissue of mevalonate uptake but that in addition the kidney may well be the major site In view of the importance of the identification of squalene as the major end-product of mevalonate in the kidneys, the squalene band isolated by thin-layer chromatography was further identified by gas-liqid chromatography using OV-17 as the stationary phase, temperature 2160 C, gas flow 100 ml/min. As shown in Fig. 8 , squalene under these conditions has an Rf of 9 min, and as is apparent at least 95% of radioactivity characterized as squalene on thin-layer chromatography is in fact found in the squalene peak of the gas-liquid chromato- (Fig. 9) . At the earlier time intervals, i.e. 1 and 2 h, the mevalonate metabolites in renal tissue conform to those found following the intravenous administration of mevalonate in that the synthesis of squalene and lanosterol by the kidney represents the predominant fate of the mevalonate. At 24 and 48 h, however, "4C in these precursors of cholesterol has decreased markedly, and the preponderance of radioactivity is now found in 27 carbon sterols, presumably cholesterol itself.
The metabolism of substrate amounts of circulating mevalonate. In order to determine whether larger concentrations of mevalonate would be similarly metabolized, the fate of this compound was examined in animals receiving 1 mg of DL-[2-'4C]mevalonate intravenously.
As indicated in Fig. 10 , the distribution and metabolism of mevalonate under these conditions is very different from that noted with smaller amounts of mevaIonic acid, in that at the 2 h time interval studied, the liver rather than the kidneys represents the major site of mevalonate metabolism. In addition, the metabolism of mevalonate in the liver, as expected, results in a preponderance of the mevalonate metabolites being present in the 27 carbon sterols, presumably cholesterol. The finding that the metabolism of these large, probably unphysiologic, doses of mevalonate leads to the liver assuming the major role in mevalonate uptake may serve to reconcile the results of the present studies with those of previous investigators (19) Sites of endogenous mevalonate production
The observation that plasma mevalonate represents an actively turning over pool, which is metabolized in the kidney, raises the question as to the tissue of origin of this endogenous mevalonate. Slices from a number of tissues were therefore incubated with [1-14C] acetate in the presence of an unlabeled pool of mevalonate and the incorporation of the labeled acetate into mevalonate was determined as described in earlier studies (4, 21) . As shown in Table II , of the tissues studied, liver has by far the greatest ability to synthesize mevalonic acid from acetate; the kidney and testes in fact had only a barely detectable rate of mevalonate synthesis, which averaged at most 1/20 of the liver. The finding that the kidney synthesizes mevalonate at only a minimal rate was of course anticipated by the observation, described in an earlier section of this study, that the conversion of acetate to sterols procedes very slowly in renal tissue. rats, and 2 h later the animals were killed and the distribution of 14C determined as previously described. The results presented in Fig. 12 demonstrate a rather striking difference in the sites of metabolism of exogenous mevalonate as compared with that of endogenous origin. While, as emphasized above, systemically administered mevalonate is metabolized primarily, by the kidneys, the results in the upper half of Fig. 12 demonstrate that after 2 h the majority of the orally administered [14C] mevalonate is present in the intestinal wall and in the liver, with significant but still lesser amounts of 1'C metabolites being found in the kidneys. The label in each of these tissues, including the intestine, is found primarily in the nonsaponifiable lipids indicating that the intestine itself must have metabolized the mevalonate delivered to it from the lumen. Moreover, fractionation of the nonsaponifiable fraction of the mevalonate metabolites, as demonstrated in the lower half of Fig. 12 , demonstrates that the [1'C]mevalonate in the intestine was present primarily as cholesterol. This was also the case with the liver. On the other hand the exogenous mevalonate reaching the kidney is metabolized, as was endogenous mevalonate, primarily to squalene and lanosterol during the time interval studied. These data suggest that orally administered mevalonate is largely metabolized by the intestine to nonsaponifiable endproducts that would be delivered, primarily via the lymph, to the systemic circulation and from there taken up preferentially by the liver. Alternately, mevalonate might be absorbed by the portal circulation and hence delivered and metabolized by the liver, and only secondarily by the kidney. To examine this question a tracer dose of [2-"C]mevalonate was administered through an intestinal venule into the portal circulation, and the distribution of lipid "C was determined. As shown in Fig.  13 , at both 1 and 2 h the kidney is the major site of mevalonate concentration; and as was observed following administration of mevalonate by the systemic route, the vast majority of the label present in the kidney has been converted to nonsaponifiable compounds. While the ratio of 14C in the kidney to that in the liver is between 3 and 4: 1 rather than the 5 and 7: 1 ratio observed following the systemic administration of labeled mevalonate, it is still apparent that most of the mevalonate administered into the portal vein must pass through the liver to be delivered to and metabolized primarily by the kidneys.
Metabolism of exogenous mevalonate
It is very likely therefore that the exogenous mevalonate that is adsorbed as such from the intestine must, like endogenous mevalonate, be chiefly metabolized in the kidneys.
Most exogenous mevalonate, however, is metabolized by the intestine before it can reach the systemic circulation. This conclusion was further supported by experiments in which a lymph cannula was inserted into a rat and the percent of administered mevalonate that was absorbed as nonsaponifiable lipid via the lymph determined.
The results shown in Table III demonstrate that over 35% of the total administered DL-mevalonate or over 70% of the L-mevalonate in the racemic mixture has been converted to nonsaponifiable material, in all probability by the intestine during the 6 h period of the experiment; moreover, of this nonsaponifiable sterol, over 18% had been delivered to the lymph during the 6 h of the experiment. Finally, it is of interest that subfractionation of nonsaponifiable "C in the lymph reveals that approximately 80% of this lipid is located in the squalene band on thin-layer chromatography.
It would seem highly likely, therefore, that exogenous mevalonate must be primarily metabolized by the intestine to cholesterol and squalene during the process of absorption. The latter lipid is then delivered to the systemic circulation via the lymph and in all probability is subsequently further metabolized by the liver to cholesterol.
DISCUSSION
The primary purpose of the present study was to determine the metabolic fate of circulating mevalonic acid in the intact animal.
Clearly, the most unexpected finding to develop from this investigation is that the kidneys represent the major organ responsible for the metabolism of circulating mevalonic acid. Despite the fact that, in contrast to the liver, the kidney has almost no capacity to synthesize mevalonate, 60-70% of the ["C] mevalonate recovered, whether the labeled compound was given intravenously or intraperitoneally, is found in the kidneys while less than 20% is accounted for in the liver. This ability of the kidney to take up mevalonate was even more clearly illustrated by the fact that per gram of tissue the kidney concentrates ["C]mevalonate to an The findings of this study obviously raise the question of the role played by the kidneys in the overall metabolism of cholesterol, a question that can only be partially resolved at present. In studies to be published in detail elsewhere),7 the concentration of mevalonate in the blood was determined using thin-layer and gas-liquid chromatography and analyzed by mass spectroscopy. In the normal rat, blood mevalonate is present at a level of approximately 5 Ag/100 ml. At a blood volume of 9.2 ml in a 200 g rat (24) then the above data would indicate that about 5% of the mevalonate escapes, presumably largely from the liver, into the plasma to comprise the circulating miscible mevalonate pool examined in the present study. It is possible that the kidney utilizes this circulating mevalonate pool to synthesis small amounts of cholesterol for structural purposes. On the other hand, both the in vivo and in vitro results demonstrate that the kidney converts squalene and lanosterol to cholesterol at a slow rate, and the evidence from the present study demonstrates that the kidney does not excrete detectable amounts of these mevalonate metabolites into the urine. It seems not improbable, therefore, that the kidney may release a portion of these cholesterol precursors into the circulation to be carried to the liver, there finally to be converted to cholesterol. Goodman's finding that significant quantities of squalene are present in the blood of both man and rat lends some support to the likelihood of such an active circulating pool of squalene in these species (27) .
It should be emphasized that, while the above conclusions are based largely on the tissue distribution of injected DL-mevalonate, i.e. the mixture of the metabolically inactive D-isomer and the active L-isomer, it is likely that the findings are physiologically sound. Examination of the tissue distribution of the metabolites of mevalonate, which could be derived only from the L-isomer, confirms the fact that the kidney is the major site of mevalonate metabolism; and secondly, the turnover studies using the physiologically active L-isomer of mevalonate confirmed the turnover data obtained initially with the racemic mevalonate.
The metabolism of exogenous mevalonate differs from that of the endogenously derived compound in that, when ingested in the diet, this sterol precuror is no longer metabolized primarily by the kidneys. Ingested mevalonate is largely converted in the intestinal wall to nonsaponifiable lipids, which are then absorbed via the lymph into the systemic circulation. It is likely therefore that the intestine rather than the kidneys plays the more important role in the primary metabolism of the small quantities of mevalonate that may be consumed in the diet.
Finally, the conclusions of this study are restricted at present only to the rat, and it remains to be determined whether the importance of the kidney in mevalonate metabolism, which has been demonstrated in this study, can be applied to other species as well.
